## Amendments to the Specification

*Please paragraphs [0022] to [0064] of the specification as filed with the following amended paragraphs:*

**[0022]** Embodiment [0022]: The present invention comprises a compound for modulating p70S6K activity according to Formula **I**,



**I**

or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein,

B, D, and E are each independently either =N- or =C($R^2$)-, provided at least one of B, D, and E is =N-;

at each occurance, each of $R^1$, $R^2$, and $R^3$ is independently selected from -H, halogen, trihalomethyl, -CN, -$NO_2$, -$OR^5$, -$N(R^5)OR^5$, -$ON(R^5)R^5$, -$N(R^5)N(R^5)R^5$, -$N(R^5)R^5$, -$S(O)_{0\text{-}2}R^5$, -$SO_2N(R^5)R^5$, -$CO_2R^5$, -$C(O)N(R^5)R^5$, -$N(R^5)SO_2R^5$, -$N(R^5)C(O)R^5$, -$N(R^5)CO_2R^5$, -$C(O)R^5$, -$C(=NR^7)N(R^5)R^5$, -$C(=NR^7)R^5$, -$C(=NR^7)OR^5$, -$N(R^5)C(=NR^7)N(R^5)R^5$, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl;

n is zero to five;

$R^4$ is selected from -H, halogen, -CN, -$NO_2$, -$N(R^5)OR^5$, -$ON(R^5)R^5$, -$N(R^5)N(R^5)R^5$, -$OR^5$, -$N(R^5)R^5$, -$S(O)_{0\text{-}2}R^5$, -$SO_2N(R^5)R^5$, -$CO_2R^5$, -$C(O)N(R^5)R^5$, -$N(R^5)SO_2R^5$, -$N(R^5)C(O)R^5$, -$N(R^5)CO_2R^5$, -$C(O)R^5$, -$C(=NR^7)N(R^5)R^5$, -$C(=NR^7)R^5$, -$C(=NR^7)OR^5$, -$N(R^5)C(=NR^7)N(R^5)R^5$, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl;

$R^2$ and $R^3$, together with the atom or atoms to which they are attached, can combine to form a three- to seven-membered optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted cycloalkyl;

$R^2$ and $R^4$, together with the atom or atoms to which they are attached, can combine to form a three- to seven-membered optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted cycloalkyl;

each $R^5$ is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, optionally substituted lower heterocyclylalkyl, and a single bond to an atom of $R^1$;

two of $R^5$, together with the atom or respective atoms to which they are attached, can combine to form an optionally substituted three- to seven-membered heterocyclic;

$R^5$ and $R^6$, together with the atom or atoms to which they are attached, can combine to form a five- to seven-membered optionally substituted heterocyclyl;

$R^5$ and $R^7$, together with the atom or atoms to which they are attached, can combine to form a five- to seven-membered optionally substituted heterocyclyl;

each of X and Y is independently selected from -C(=O)-, $-C(R^6)R^6$-, -O-, $-N(R^5)$-, $-C(=NR^7)$-, and $-S(O)_{0-2}$-; provided when X is -O- or $-N(R^5)$-, then Y cannot be $-C(H)R^{6a}$-, where $R^{6a}$ is $-C(R^{20})(R^{21})R^{22}$ wherein at least one of $R^{20}$, $R^{21}$ and $R^{22}$ is selected from phenyl, napthyl, cyclohexyl, dihydronapthyl tetrahydronapthyl, and a five- to six-membered heteroaryl, each optionally substituted;

or X and Y can combine to form either $-C(R^6)=C(R^6)$- or -C≡C-;

Z is selected from O, S, and a double bond to an atom of $R^1$;

A is either $-N(R^5)$- or a single bond;

each $R^6$ is independently selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^5$, $-N(R^5)R^5$, $-S(O)_{0-2}R^5$, $-SO_2N(R^5)R^5$, $-CO_2R^5$, $-C(O)N(R^5)R^5$, $-N(R^5)SO_2R^5$, $-N(R^5)C(O)R^5$, $-N(R^5)CO_2R^5$, $-C(O)R^5$, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted arylalkyl, and a single bond to an atom of $R^2$ of D or E when said either D or E is $=C(R^2)$-;

two of $R^6$, together with the atom or atoms to which they are attached, can combine to form one of an optionally substituted three to seven-membered alicylic, an optionally substituted three to seven-membered heteroalicylic, and a double bond to an atom of $R^2$ of D or E when said either D or E is $=C(R^2)$-;

each $R^7$ is independently selected from -H, -CN, $-NO_2$, $-N(R^5)R^5$, $-OR^5$, $-S(O)_{0-2}R^5$, $-SO_2N(R^5)R^5$, $-CO_2R^5$, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, and a single bond to a carbon of J; and

J is selected from an optionally substituted five- to ten-membered aryl and an optionally substituted five- to ten-membered heteroaryl;

provided the compound is not one of: 2-(2-amino-5-cyano-6-methylsulfanyl-pyrimidin-4-ylsulfanyl)-N-(3-trifluoromethyl-phenyl)-acetamide, 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[3-(butyloxy)phenyl]acetamide, 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-1,3-benzothiazol-2-ylacetamide, 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-(5-ethyl-1,3,4-thiadiazol-2-yl)acetamide, 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 2-amino-4-{[2-(3,5-dimethyl-1H-pyrazol-1-yl)-2-oxoethyl]thio}-6-(methylthio)pyrimidine-5-carbonitrile, 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-1,3-thiazol-2-ylacetamide, 2-(5-cyano-2-methylsulfanyl-pyrimidin-4-ylsulfanyl)-N-phenyl-acetamide, 5-amino-2-methylsulfanyl-thieno[2,3-d]pyrimidine-6-carboxylic acid phenylamide, 2-(6-amino-5-cyano-2-methylsulfanyl-pyrimidin-4-ylsulfanyl)-N-phenyl-acetamide, 4,5-diamino-2-(2-methoxy-ethoxy)-thieno[2,3-d]pyrimidine-6-carboxylic acid phenylamide, 2-(5-cyano-6-phenyl-2-phenylcarbamoylmethylsulfanyl-pyrimidin-4-ylsulfanyl)-N-phenyl-acetamide, and a 2-(6-amino-3,5-dicyano-pyridin-2-ylsulfanyl)-N-phenyl-acetamide derivative.

**[0023]** Embodiment [0023]: In one example, the compound is according to ~~paragraph~~ Embodiment [0022], wherein J is either a six-membered aryl or a five- to six-membered heteroaryl.

**[0024]** Embodiment [0024]: In another example, the compound is according to ~~paragraph~~ Embodiment [0023], wherein D is $=C(R^2)$-.

**[0025]** Embodiment [0025]: In another example, the compound is according to ~~paragraph~~ Embodiment [0024], wherein $R^4$ is $-N(R^5)R^5$.

**[0026]** Embodiment [0026]: In another example, the compound is according to ~~paragraph~~ Embodiment [0025], of Formula **II**,



**II**

wherein, $R^1$, $R^2$, $R^3$, $R^5$, n, B, E, X, and Y are as defined above; and Q is either =N- or =C(H)-.

**[0027]** Embodiment [0027]: In another example, the compound is according to ~~paragraph~~ Embodiment [0026], wherein $R^{2a}$ is selected from halogen, -CN, $-C(=O)N(R^5)R^5$, $-CF_3$, $-CO_2R^5$, $-C(R^5)=C(R^5)R^5$, $-C\equiv C-R^5$, and $-NO_2$;

**[0028]** Embodiment [0028]: In another example, the compound is according to ~~paragraph~~ Embodiment [0027], wherein at least one of $R^{5a}$ and $R^{5b}$ is -H.

**[0029]** Embodiment [0029]: In another example, the compound is according to ~~paragraph~~ Embodiment [0028], wherein $R^3$ is selected from $-OR^5$, $-NR^5R^5$, and $-S(O)_{0\text{-}2}R^5$.

**[0030]** Embodiment [0030]: In another example, the compound is according to ~~paragraph~~ Embodiment [0029], wherein at least one of B and E is =N-.

**[0031]** Embodiment [0031]: In another example, the compound is according to ~~paragraph~~ Embodiment [0030], wherein $R^1$ is selected from halogen, $-OR^5$, $-NR^5R^5$, $-S(O)_{0\text{-}2}R^5$, $-NO_2$, perhaloalkyl, optionally substituted lower alkyl, optionally substituted aryl, and optionally substituted arylalkyl.

**[0032]** Embodiment [0032]: In another example, the compound is according to ~~paragraph~~ Embodiment [0031], wherein $R^1$ is selected from halogen, $-OR^5$, $-NR^5R^5$, $-S(O)_{0\text{-}1}R^5$, $-NO_2$, perhaloalkyl, and optionally substituted lower alkyl.

**[0033]** Embodiment [0033]: In another example, the compound is according to ~~paragraph~~ Embodiment [0032], wherein A is $-N(R^5)-$.

**[0034]** Embodiment [0034]: In another example, the compound is according to Embodiment ~~paragraph~~ [0033], of Formula **III**,



**III**

wherein, $R^3$, $R^5$, X, Y, and Q are as defined above; $R^{1a}$ is selected from halogen, lower perfluoroalkyl, $-NO_2$, $-OR^5$, and optionally substituted $C_{1-4}$alkyl; and $R^{1b}$ is selected from halogen, $-OR^5$, $-N(R^5)R^5$, $-SR^5$, perfluoroalkyl, and optionally substituted lower alkyl.

**[0035]** Embodiment [0035]: In another example, the compound is according to Embodiment ~~paragraph~~ [0034], wherein $R^{1a}$ is selected from $-NO_2$, halogen, perfluoroalkyl, haloalkyl, optionally substituted $C_{1-2}$alkyl, and optionally substituted -O-$C_{1-2}$alkyl.

**[0036]** Embodiment [0036]: In another example, the compound is according to Embodiment ~~paragraph~~ [0035], wherein $R^3$ is selected from optionally substituted -O-$C_{1-4}$alkyl, -O-$C_{1-4}$perfluoroalkyl, optionally substituted -N(H)$C_{1-4}$alkyl, optionally substituted -N($C_{1-4}$alkyl)$C_{1-4}$alkyl, optionally substituted -S(O)$_{0-2}$-$C_{1-4}$alkyl, and optionally substituted -S(O)$_{0-2}$-$C_{1-4}$perfluoroalkyl.

**[0037]** Embodiment [0037]: In another example, the compound is according to Embodiment ~~paragraph~~ [0036], wherein Y is either -N(H)- or $-C(R^6)R^6$-.

**[0038]** Embodiment [0038]: In another example, the compound is according to Embodiment ~~paragraph~~ [0037], wherein X is selected from -O-, $-N(R^5)$- and -S-.

**[0039]** Embodiment [0039]: In another example, the compound is according to Embodiment ~~paragraph~~ [0038], wherein Y is $-C(R^6)R^6$-; wherein each $R^6$ is independently selected from -H, halogen, trihalomethyl, $-NH_2$, optionally substituted -O-$C_{1-4}$alkyl, optionally substituted -N(H)$C_{1-4}$alkyl, optionally substituted -S-$C_{1-4}$alkyl, optionally substituted lower alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclylalkyl.

**[0040]** Embodiment [0040]: In another example, the compound is according to Embodiment ~~paragraph~~ [0039], wherein Y is -C(H)$R^6$-; wherein $R^6$ is independently selected from -H, halogen, trihalomethyl, $-NH_2$, optionally substituted -O-$C_{1-4}$alkyl, optionally substituted -N(H)$C_{1-4}$alkyl, optionally substituted -S-$C_{1-4}$alkyl, optionally substituted lower alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclylalkyl.

**[0041]** Embodiment [0041]: In another example, the compound is according to Embodiment ~~paragraph~~ [0040], wherein Q is =C(H)-.

**[0042]** Embodiment [0042]: In another example, the present invention comprises a compound for modulating p70S6K activity according to Formula **IV**,



**IV**

or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein,

$R^1$ is selected from halogen, $-OR^5$, $-N(R^5)R^5$, $-S(O)_{0-2}R^5$, $-NO_2$, $-C(O)R^5$, perhaloalkyl, optionally substituted lower alkyl, optionally substituted aryl, and optionally substituted arylalkyl.

n is zero to five;

$R^2$ is selected from halogen, -CN, $-C(=O)N(R^5)R^5$, $-CF_3$, $-CO_2R^5$, $-C(R^5)=C(R^5)R^5$, $-C\equiv C-R^5$, and $-NO_2$;

$R^3$ is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-OR^5$, $-N(R^5)OR^5$, $-ON(R^5)R^5$, $-N(R^5)N(R^5)R^5$, $-N(R^5)R^5$, $-S(O)_{0-2}R^5$, $-SO_2N(R^5)R^5$, $-CO_2R^5$, $-C(O)N(R^5)R^5$, $-N(R^5)SO_2R^5$, $-N(R^5)C(O)R^5$, $-N(R^5)CO_2R^5$, $-C(O)R^5$, $-C(=NR^7)N(R^5)R^5$, $-C(=NR^7)R^5$, $-C(=NR^7)OR^5$, $-N(R^5)C(=NR^7)N(R^5)R^5$, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl;

$R^4$ is selected from -CN, halogen, $-NO_2$, $-N(R^5)OR^5$, $-ON(R^5)R^5$, $-N(R^5)N(R^5)R^5$, $-OR^5$, $-N(R^5)R^5$, $-SO_2N(R^5)R^5$, $-C(O)N(R^5)R^5$, $-C(=NR^7)N(R^5)R^5$, $-C(=NR^7)R^5$, $-C(=NR^7)OR^5$,

$-N(R^5)C(=NR^7)N(R^5)R^5$, optionally substituted lower alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclylalkyl;

each $R^5$ is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;

two of $R^5$, together with the atom or respective atoms to which they are attached, can combine to form an optionally substituted three- to seven-membered heterocyclic;

$R^5$ and $R^6$, together with the atom or atoms to which they are attached, can combine to form a five- to seven-membered optionally substituted heterocyclyl;

$R^5$ and $R^7$, together with the atom or atoms to which they are attached, can combine to form a five- to seven-membered optionally substituted heterocyclyl;

each of X and Y is independently selected from $-C(=O)-$, $-C(R^6)R^6-$, -O-, $-N(R^5)-$, $-C(=NR^7)-$, and $-S(O)_{0-2}-$; provided when X is -O- or $-N(R^5)-$, then Y cannot be $-C(H)R^{6a}-$, where $R^{6a}$ is $-C(R^{20})(R^{21})R^{22}$ wherein at least one of $R^{20}$, $R^{21}$ and $R^{22}$ is selected from phenyl, napthyl, cyclohexyl, dihydronapthyl tetrahydronapthyl, and a five- to six-membered heteroaryl, each optionally substituted;

or X and Y can combine to form either $-C(R^6)=C(R^6)-$ or $-C\equiv C-$;

each $R^6$ is independently selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^5$, $-N(R^5)R^5$, $-S(O)_{0-2}R^5$, $-SO_2N(R^5)R^5$, $-CO_2R^5$, $-C(O)N(R^5)R^5$, $-N(R^5)SO_2R^5$, $-N(R^5)C(O)R^5$, $-N(R^5)CO_2R^5$, $-C(O)R^5$, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted arylalkyl, and a single bond to an atom of $R^1$;

two of $R^6$, together with the atom or atoms to which they are attached, can combine to form either an optionally substituted three to seven-membered alicylic or an optionally substituted three to seven-membered heteroalicylic;

each $R^7$ is independently selected from -H, -CN, $-NO_2$, $-N(R^5)R^5$, $-OR^5$, $-S(O)_{0-2}R^5$, $-SO_2N(R^5)R^5$, $-CO_2R^5$, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, and a single bond to a carbon of J; and

J is selected from an optionally substituted five- to ten-membered aryl and an optionally substituted five- to ten-membered heteroaryl;

provided the compound is not one of: 2-(2-amino-5-cyano-6-methylsulfanyl-pyrimidin-4-ylsulfanyl)-N-(3-trifluoromethyl-phenyl)-acetamide, 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[3-(butyloxy)phenyl]acetamide, 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-1,3-benzothiazol-2-ylacetamide, 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-(5-ethyl-1,3,4-thiadiazol-2-yl)acetamide, 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 2-amino-4-{[2-(3,5-dimethyl-1H-pyrazol-1-yl)-2-oxoethyl]thio}-6-(methylthio)pyrimidine-5-carbonitrile, 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-1,3-thiazol-2-ylacetamide, 2-(5-cyano-2-methylsulfanyl-pyrimidin-4-ylsulfanyl)-N-phenyl-acetamide, 5-amino-2-methylsulfanyl-thieno[2,3-d]pyrimidine-6-carboxylic acid phenylamide, 2-(6-amino-5-cyano-2-methylsulfanyl-pyrimidin-4-ylsulfanyl)-N-phenyl-acetamide, 4,5-diamino-2-(2-methoxy-ethoxy)-thieno[2,3-d]pyrimidine-6-carboxylic acid phenylamide, 2-(5-cyano-6-phenyl-2-phenylcarbamoylmethylsulfanyl-pyrimidin-4-ylsulfanyl)-N-phenyl-acetamide, and a 2-(6-amino-3,5-dicyano-pyridin-2-ylsulfanyl)-N-phenyl-acetamide derivative.

**[0043]** Embodiment [0043]: In another example, the compound is according to Embodiment ~~paragraph~~ [0042], wherein $R^4$ is $-NR^{5a}R^{5b}$; wherein at least one of $R^{5a}$ and $R^{5b}$ is -H.

**[0044]** Embodiment [0044]: In another example, the compound is according to Embodiment ~~paragraph~~ [0043], wherein X is selected from -O-, $-N(R^5)-$, and $-S(O)_{0-2}-$.

**[0045]** Embodiment [0045]: In another example, the compound is according to Embodiment ~~paragraph~~ [0044], wherein Y is either $-C(R^6)R^6-$ or $-N(R^5)-$.

**[0046]** Embodiment [0046]: In another example, the compound is according to Embodiment ~~paragraph~~ [0045], wherein J is either phenyl or pyridyl.

**[0047]** Embodiment [0047]: In another example, the compound is according to Embodiment ~~paragraph~~ [0046], wherein $R^4$ is $-NH_2$.

**[0048]** Embodiment [0048]: In another example, the compound is according to Embodiment ~~paragraph~~ [0047], wherein at least one of $R^1$ is selected from halo, $-NO_2$, $-OR^5$, perfluoroalkyl, haloalkyl, and optionally substituted $C_{1-4}$alkyl.

**[0049]** Embodiment [0049]: In another example, the compound is according to Embodiment ~~paragraph~~ [0048], of Formula V,



V

wherein $R^1$, $R^3$, X, and Y are as defined above; and Q is either =N- or =C(H)-.

**[0050]** Embodiment [0050]: In another example, the compound is according to Embodiment ~~paragraph~~ [0049], wherein $R^{1a}$ is selected from halo, lower perfluoroalkyl, $-NO_2$, optionally substituted $-O-C_{1-4}$alkyl, and optionally substituted $C_{1-4}$alkyl.

**[0051]** Embodiment [0051]: In another example, the compound is according to Embodiment ~~paragraph~~ [0050], wherein $R^3$ is selected from optionally substituted $-O-C_{1-4}$alkyl, $-O-C_{1-4}$perfluoroalkyl, optionally substituted $-N(H)C_{1-4}$alkyl, optionally substituted $-N(C_{1-4}alkyl)C_{1-4}$alkyl, optionally substituted $-S(O)_{0-2}-C_{1-4}$alkyl, and optionally substituted $-S(O)_{0-2}-C_{1-4}$perfluoroalkyl.

**[0052]** Embodiment [0052]: In another example, the compound is according to Embodiment ~~paragraph~~ [0051], wherein Y is $-C(R^6)R^6-$; wherein each $R^6$ is independently selected from -H, halogen, trihalomethyl, $-NH_2$, optionally substituted $-O-C_{1-4}$alkyl, optionally substituted $-N(H)C_{1-4}$alkyl, optionally substituted $-S-C_{1-4}$alkyl, optionally substituted lower alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclylalkyl.

**[0053]** Embodiment [0053]: In another example, the compound is according to Embodiment ~~paragraph~~ [0052], wherein Y is $-C(H)R^6-$; wherein $R^6$ is independently selected from -H, halogen, trihalomethyl, $-NH_2$, optionally substituted $-O-C_{1-4}$alkyl, optionally substituted $-N(H)C_{1-4}$alkyl, optionally substituted $-S-C_{1-4}$alkyl, optionally substituted lower alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclylalkyl.

**[0054]** Embodiment [0054]: In another example, the compound is according to Embodiment ~~paragraph~~ [0053], wherein Q is =C(H)-.

**[0055]** Embodiment [0055]: In another example, the compound is according to Embodiment ~~paragraph~~ [0022], selected from

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 1 | 2-[(3-cyano-4,6-dimethyl-5-nitropyridin-2-yl)oxy]-N-[3-(trifluoromethyl)phenyl]acetamide |  |
| 2 | N-2-(2-amino-6-chloropyrimidin-4-yl)-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 3 | [2-amino-6-(methylthio)pyrimidin-4-yl]methyl [3-(trifluoromethyl)phenyl]carbamate |  |
| 4 | 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[5-(trifluoromethyl)pyridin-2-yl]acetamide |  |
| 5 | N-2-[2-amino-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 6 | 2-{[2-amino-6-(methylthio)pyrimidin-4-yl]oxy}-N-[3-(trifluoromethyl)phenyl]acetamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 7 | 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[3-(methyloxy)phenyl]acetamide |  |
| 8 | N-2-(2-amino-6-morpholin-4-ylpyrimidin-4-yl)-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 9 | 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-(4-chlorophenyl)acetamide |  |
| 10 | 2-{[2-amino-6-(1H-1,2,3-benzotriazol-1-yloxy)pyrimidin-4-yl]thio}-N-[3-(trifluoromethyl)phenyl]acetamide |  |
| 11 | 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-(3-chlorophenyl)acetamide |  |
| 12 | N-2-(2-amino-6-chloro-5-formylpyrimidin-4-yl)-N-[3-(trifluoromethyl)phenyl]glycinamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 13 | N-2-[2-amino-5-formyl-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 14 | 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]oxy}-N-[3-(trifluoromethyl)phenyl]acetamide |  |
| 15 | 2-[(2-amino-6-chloropyrimidin-4-yl)thio]-N-[3-(trifluoromethyl)phenyl]acetamide |  |
| 16 | 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-methyl-N-[3-(trifluoromethyl)phenyl]acetamide |  |
| 17 | N-2-[4-amino-6-(methylthio)-1,3,5-triazin-2-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 18 | N-2-[4-(dimethylamino)-6-(methylthio)-1,3,5-triazin-2-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 19 | N-2-[4-(methylamino)-6-(methylthio)-1,3,5-triazin-2-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 20 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 21 | '2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[3-(trifluoromethyl)phenyl]acetamide |  |
| 22 | '2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[3-(butyloxy)phenyl]acetamide |  |
| 23 | '2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-1,3-benzothiazol-2-ylacetamide |  |
| 24 | '2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-(5-ethyl-1,3,4-thiadiazol-2-yl)acetamide |  |
| 25 | '2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-(4-methyl-1,3-thiazol-2-yl)acetamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 26 | '2-amino-4-{[2-(3,5-dimethyl-1H-pyrazol-1-yl)-2-oxoethyl]thio}-6-(methylthio)pyrimidine-5-carbonitrile |  |
| 27 | '2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-1,3-thiazol-2-ylacetamide |  |
| 28 | ethyl 5-[({[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}acetyl)amino]-4-cyano-3-methylthiophene-2-carboxylate |  |
| 29 | 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-pyridin-2-ylacetamide |  |
| 30 | 2-amino-4-({2-[2,5-bis(methyloxy)phenyl]-2-oxoethyl}thio)-6-(methylthio)pyrimidine-5-carbonitrile |  |
| 31 | 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[4-fluoro-3-(trifluoromethyl)phenyl]acetamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 32 | 2-[(2,6-diaminopyrimidin-4-yl)thio]-N-[4-fluoro-3-(trifluoromethyl)phenyl]acetamide |  |
| 33 | 2-[(2,6-diaminopyrimidin-4-yl)thio]-N-[3-(trifluoromethyl)phenyl]acetamide |  |
| 34 | 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[4-chloro-3-(trifluoromethyl)phenyl]acetamide |  |
| 35 | 2-amino-4-(methylthio)-6-({2-oxo-1-[3-(trifluoromethyl)phenyl]pyrrolidin-3-yl}thio)pyrimidine-5-carbonitrile |  |
| 36 | 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[6-(trifluoromethyl)pyridin-2-yl]acetamide |  |
| 37 | 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[4-(trifluoromethyl)pyridin-2-yl]acetamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 38 | {6-(methylthio)-2-[(phenylmethyl)amino]pyrimidin-4-yl}methyl [3-(trifluoromethyl)phenyl]carbamate |  |
| 39 | [6-(methylamino)-2-(methylthio)pyrimidin-4-yl]methyl [3-(trifluoromethyl)phenyl]carbamate |  |
| 40 | {2-(methylthio)-6-[(phenylmethyl)amino]pyrimidin-4-yl}methyl [3-(trifluoromethyl)phenyl]carbamate |  |
| 41 | 2-{[2-(acetylamino)-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[3-(trifluoromethyl)phenyl]acetamide |  |
| 42 | (2S)-2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]oxy}-N-[3-(trifluoromethyl)phenyl]propanamide |  |
| 43 | 2-[(2-amino-6-chloro-5-formylpyrimidin-4-yl)thio]-N-[3-(trifluoromethyl)phenyl]acetamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 44 | N-2-[2-amino-5-(hydroxymethyl)-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 45 | 2-{[2-amino-5-formyl-6-(methylamino)pyrimidin-4-yl]thio}-N-[3-(trifluoromethyl)phenyl]acetamide |  |
| 46 | 2-{[2-amino-5-formyl-6-(methylthio)pyrimidin-4-yl]oxy}-N-[3-(trifluoromethyl)phenyl]acetamide |  |
| 47 | 2-{[4-amino-6-(methylthio)-1,3,5-triazin-2-yl]oxy}-N-[3-(trifluoromethyl)phenyl]acetamide |  |
| 48 | 2-{[2-amino-6-(methylthio)pyrimidin-4-yl]thio}-N-[3-(trifluoromethyl)phenyl]acetamide |  |
| 49 | 2-amino-4-(methylthio)-6-{[2-oxo-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)ethyl]thio}pyrimidine-5-carbonitrile |  |
| 50 | 2-[(2-amino-6-chloro-5-formylpyrimidin-4-yl)oxy]-N-[3-(trifluoromethyl)phenyl]acetamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 51 | 2-{[2-amino-5-formyl-6-(phenylthio)pyrimidin-4-yl]thio}-N-[3-(trifluoromethyl)phenyl]acetamide |  |
| 52 | 2-{[2-amino-5-(hydroxymethyl)-6-(phenylthio)pyrimidin-4-yl]thio}-N-[3-(trifluoromethyl)phenyl]acetamide |  |
| 53 | 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[2-methyl-3-(trifluoromethyl)phenyl]acetamide |  |
| 54 | 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[2-(methyloxy)-5-(trifluoromethyl)phenyl]acetamide |  |
| 55 | 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[2-chloro-5-(trifluoromethyl)phenyl]acetamide |  |
| 56 | 2-{[2-amino-5-(hydroxymethyl)-6-(methylthio)pyrimidin-4-yl]oxy}-N-[3-(trifluoromethyl)phenyl]acetamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 57 | N-2-(6-amino-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 58 | N-2-[2-amino-5-[(E)-hydrazonomethyl]-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 59 | N-2-[2-amino-5-[(E)-(hydroxyimino)methyl]-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 60 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  |
| 61 | 2-{[2-amino-5-cyano-6-(methylamino)pyrimidin-4-yl]thio}-N-[3-(trifluoromethyl)phenyl]acetamide |  |
| 62 | 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[2-amino-5-(trifluoromethyl)phenyl]acetamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 63 | 2-amino-4-(methylthio)-6-({[6-(trifluoromethyl)-1H-benzimidazol-2-yl]methyl}thio)pyrimidine-5-carbonitrile |  |
| 64 | 2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]hydrazinecarboxamide |  |
| 65 | N-2-[5-cyano-2-(methylamino)-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 66 | 2-{[2-amino-5-cyano-6-(dimethylamino)pyrimidin-4-yl]thio}-N-[3-(trifluoromethyl)phenyl]acetamide |  |
| 67 | (S)-1-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]prolinamide |  |
| 68 | (2R)-2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]oxy}-N-[3-(trifluoromethyl)phenyl]propanamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 69 | 1-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]oxy}-N-[3-(trifluoromethyl)phenyl]cyclopropane carboxamide |  |
| 70 | (2S)-2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]oxy}-3-methyl-N-[3-(trifluoromethyl)phenyl]butanamide |  |
| 71 | N-2-[5-cyano-2-(dimethylamino)-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 72 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-2-methyl-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 73 | 1-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]amino}-N-[3-(trifluoromethyl)phenyl]cyclopropane carboxamide |  |
| 74 | N-2-[2-amino-5-cyano-6-(methylsulfinyl)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 75 | N-2-[2-amino-5-cyano-6-(methylsulfonyl)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  |
| 76 | N-2-(5-cyano-2-morpholin-4-ylpyrimidin-4-yl)-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 77 | 2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[3,5-bis(trifluoromethyl)phenyl]acetamide |  |
| 78 | N-2-[2-amino-5-cyano-6-(methyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  |
| 79 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[2-(methyloxy)-5-(trifluoromethyl)phenyl]-L-alaninamide |  |
| 80 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[2-chloro-5-(trifluoromethyl)phenyl]-L-alaninamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 81 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-2-methyl-N-[3-(trifluoromethyl)phenyl]alaninamide |  |
| 82 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-{3-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-L-alaninamide |  |
| 83 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-D-alaninamide |  |
| 84 | 2-[(2-amino-5-cyano-6-morpholin-4-ylpyrimidin-4-yl)thio]-N-[3-(trifluoromethyl)phenyl]acetamide |  |
| 85 | (R)-1-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]prolinamide |  |
| 86 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 87 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-2-[2-(dimethylamino)ethyl]-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 88 | N-2-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  |
| 89 | N-2-(2,6-diamino-5-cyanopyrimidin-4-yl)-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  |
| 90 | N-2-(2-amino-5-cyanopyrimidin-4-yl)-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  |
| 91 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-2-methyl-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  |
| 92 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-(3-{[2-(diethylamino)ethyl]oxy}phenyl)-L-alaninamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 93 | 2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-1,2-dimethyl-N-[3-(trifluoromethyl)phenyl]hydrazinecarboxamide |  |
| 94 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-amino-5-(trifluoromethyl)phenyl]-L-alaninamide |  |
| 95 | ethyl [1-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-2-({[3-(trifluoromethyl)phenyl]amino}carbonyl)hydrazino]acetate |  |
| 96 | 2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-2-methyl-N-[3-(trifluoromethyl)phenyl]hydrazinecarboxamide |  |
| 97 | 3,5-diamino-4,6-dimethyl-N-[3-(trifluoromethyl)phenyl]furo[2,3-b]pyridine-2-carboxamide |  |
| 98 | 3-amino-4,6-dimethyl-5-nitro-N-[3-(trifluoromethyl)phenyl]furo[2,3-b]pyridine-2-carboxamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 99 | N-2-(2-amino-5-cyano-6-hydroxypyrimidin-4-yl)-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  |
| 100 | N-2-[5-cyano-2-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 101 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-2-(tetrahydro-2H-pyran-4-ylmethyl)-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 102 | N-2-(2-amino-5-cyano-6-{[2-(dimethylamino)ethyl]oxy}pyrimidin-4-yl)-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  |
| 103 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-6-{[(1,1-dimethylethyl)oxy]carbonyl}-N-[3-(trifluoromethyl)phenyl]-L-lysinamide |  |
| 104 | 2-amino-4-(methylthio)-6-(methyl{(1S)-1-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl}amino)pyrimidine-5-carbonitrile |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 105 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-2-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-N-[3-(trifluoromethyl)phenyl]glycinamide |  |
| 106 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-{[2-(diethylamino)ethyl]amino}-5-(trifluoromethyl)phenyl]-L-alaninamide |  |
| 107 | 2-amino-4-(methylthio)-6-({(1S)-1-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl}amino)pyrimidine-5-carbonitrile |  |
| 108 | 2-{2-amino-5-cyano-6-[1-(3-trifluoromethyl-phenylcarbamoyl)-1S-ethylamino]-pyrimidin-4-ylamino}-N-(3-trifluoromethyl-phenyl)-2S-propionamide |  |
| 109 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-2-methyl-N-(3-methylphenyl)glycinamide |  |
| 110 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-2-methyl-N-[3-(1-methylethyl)phenyl]glycinamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 111 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-5-[imino(nitroamino)methyl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide |  |
| 112 | methyl 3-({N-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-L-alanyl}amino)-5-(trifluoromethyl)benzoate |  |
| 113 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-(3-nitrophenyl)-L-alaninamide |  |
| 114 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-lysinamide |  |
| 115 | N-2-[2-amino-5-cyano-6-(propyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  |
| 116 | N-2-[5-cyano-2-{[2-(methyloxy)ethyl]amino}-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 117 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-argininamide |  |
| 118 | N-2-[2-amino-5-cyano-6-(methylsulfinyl)pyrimidin-4-yl]-N-2-methyl-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  |
| 119 | N-2-[2-amino-5-cyano-6-(methyloxy)pyrimidin-4-yl]-N-2-methyl-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  |
| 120 | N-2-[2-amino-5-cyano-6-(propyloxy)pyrimidin-4-yl]-N-2-methyl-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  |
| 121 | N-2-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-2-methyl-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  |
| 122 | N-2-{2-amino-5-cyano-6-[(1-methylethyl)oxy]pyrimidin-4-yl}-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 123 | N-5-acetyl-N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide |  |
| 124 | N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-(3-aminophenyl)-L-alaninamide |  |
| 125 | 3-({N-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-L-alanyl}amino)-N-[2-(dimethylamino)ethyl]-5-(trifluoromethyl)benzamide |  |
| 126 | 2-(methyloxy)ethyl ((4S)-4-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]amino}-5-oxo-5-{[3-(trifluoromethyl)phenyl]amino}pentyl)carbamate |  |
| 127 | 2-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]hydrazinecarboxamide |  |
| 128 | 1,1-dimethylethyl ((4S)-4-{[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]amino}-5-oxo-5-{[3-(trifluoromethyl)phenyl]amino}pentyl)carbamate |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 129 | N-2-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide |  |
| 130 | 3-({N-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-methyl-L-alanyl}amino)-N-[2-(dimethylamino)ethyl]-5-(trifluoromethyl)benzamide | Chiral  |
| 131 | 3-({N-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-methyl-L-alanyl}amino)-N-[3-(4-methylpiperazin-1-yl)propyl]-5-(trifluoromethyl)benzamide | Chiral  |
| 132 | N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N~2~-methyl-N-{3-[(trifluoromethyl)oxy]phenyl}-L-alaninamide | Chiral  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 133 | N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-(3-bromophenyl)-N~2~-methyl-L-alaninamide |  |
| 134 | N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-{2-[(2-(dimethylamino)ethyl]oxy}-5-[(trifluoromethyl)oxy]phenyl}-N~2~-methyl-L-alaninamide |  |
| 135 | 3-({N-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-methyl-L-alanyl}amino)-N-(2-morpholin-4-ylethyl)-5-(trifluoromethyl)benzamide |  |
| 136 | N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N~2~-methyl-N-[3-(trifluoromethyl)phenyl]-L-lysinamide |  |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 137 | N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-{[2-(dimethylamino)ethyl]oxy}-5-(trifluoromethyl)phenyl]-L-alaninamide |  Chiral |
| 138 | (2S)-2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]amino}-3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl acetate |  Chiral |
| 139 | N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N~1~-[3-(trifluoromethyl)phenyl]-L-glutamamide |  Chiral |
| 140 | 2-[2-amino-5-cyano-6-(methyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]hydrazinecarboxamide |  |
| 141 | 3-({N-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-L-alanyl}amino)-N-hydroxy-5-(trifluoromethyl)benzamide |  Chiral |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 142 | N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-3-(dimethylamino)-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  Chiral |
| 143 | N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-5-morpholin-4-yl-N-[3-(trifluoromethyl)phenyl]-L-norvalinamide |  Chiral |
| 144 | N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N~5~-[2-(methyloxy)ethyl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide |  Chiral |
| 145 | 3-({N-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-L-alanyl}amino)-5-(trifluoromethyl)benzoic acid |  Chiral |
| 146 | methyl N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alpha-glutaminate |  Chiral |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 147 | N~5~~(aminocarbonyl)-N~2~~[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide |  Chiral |
| 148 | N~2~~[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide |  Chiral |
| 149 | N~2~~[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alpha-glutamine |  Chiral |
| 150 | N~2~~[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-serinamide |  Chiral |
| 151 | N~2~~[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-O-(phenylmethyl)-N-[3-(trifluoromethyl)phenyl]-L-serinamide |  Chiral |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 152 | N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-argininamide |  Chiral |
| 153 | N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N~2~-methyl-N~6~-{[(phenylmethyl)oxy]carbonyl}-N-[3-(trifluoromethyl)phenyl]-L-lysinamide |  Chiral |
| 154 | Nalpha-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-tyrosinamide |  Chiral |
| 155 | N~5~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide |  Chiral |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 156 | N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N~6~,N~6~-dimethyl-N-[3-(trifluoromethyl)phenyl]-L-lysinamide |  Chiral |
| 157 | N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-[(4-methylpiperazin-1-yl)carbonyl]-5-(trifluoromethyl)phenyl]-L-alaninamide |  Chiral |
| 158 | 3-({N-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-L-alanyl}amino)-N-(3-pyrrolidin-1-ylpropyl)-5-(trifluoromethyl)benzamide |  Chiral |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 159 | 3-({N-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-L-alanyl}amino)-N-(2-morpholin-4-ylethyl)-5-(trifluoromethyl)benzamide |  Chiral |
| 160 | 3-({N-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-L-alanyl}amino)-N-[2-(dimethylamino)ethyl]-5-(trifluoromethyl)benzamide |  Chiral |
| 161 | 3-({N-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-L-alanyl}amino)-N-[3-(4-methylpiperazin-1-yl)propyl]-5-(trifluoromethyl)benzamide |  Chiral |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 162 | N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N~2~-methyl-N~6~-{[(phenylmethyl)oxy]carbonyl}-N-[3-(trifluoromethyl)phenyl]-L-lysinamide |  Chiral |
| 163 | 1,1-dimethylethyl ((4S)-4-{[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]amino}-5-oxo-5-{[3-(trifluoromethyl)phenyl]amino}pentyl)carbamate |  Chiral |
| 164 | (2S)-2-{[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]amino}-3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl acetate |  Chiral |
| 165 | phenylmethyl N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alpha-glutaminate |  Chiral |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 166 | N~2~,N~5~-diacetyl-N~2~-[2-(acetylamino)-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide |  Chiral |
| 167 | 2-(methyloxy)ethyl ((4S)-4-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]amino}-5-oxo-5-{[3-(trifluoromethyl)phenyl]amino}pentyl)carbamate |  Chiral |
| 168 | N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-5-morpholin-4-yl-N-[3-(trifluoromethyl)phenyl]-L-norvalinamide |  Chiral |
| 169 | N-((4S)-4-{[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]amino}-5-oxo-5-{[3-(trifluoromethyl)phenyl]amino}pentyl)-N,N-dimethylmethanaminium |  Chiral |
| 170 | Methyl N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alpha-glutaminate |  Chiral |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 171 | N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N~6~,N~6~-dimethyl-N-[3-(trifluoromethyl)phenyl]-L-lysinamide |  Chiral |
| 172 | N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N~2~-methyl-N-{3-[(trifluoromethyl)oxy]phenyl}-L-alaninamide |  Chiral |
| 173 | N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alpha-glutamine |  Chiral |
| 174 | N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-(3-bromophenyl)-N~2~-methyl-L-alaninamide |  Chiral |
| 175 | N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N~1~-[3-(trifluoromethyl)phenyl]-L-glutamamide |  Chiral |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 176 | N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-3-(dimethylamino)-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  Chiral |
| 177 | '2-(2-amino-5-cyano-6-ethoxy-pyrimidin-4-ylamino)-4-hydrazinocarbonyl-N-(3-trifluoromethyl-phenyl)-butyramide |  Chiral |
| 178 | N~2~-[2-amino-5-cyano-6-(methyloxy)pyrimidin-4-yl]-3-(dimethylamino)-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  Chiral |
| 179 | N~2~-[2-amino-5-cyano-6-(methyloxy)pyrimidin-4-yl]-N-[3-{[2-(dimethylamino)ethyl]oxy}-5-(trifluoromethyl)phenyl]-L-alaninamide |  Chiral |
| 180 | N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-{[2-(dimethylamino)ethyl]oxy}-5-(trifluoromethyl)phenyl]-L-alaninamide |  Chiral |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 181 | N~2~-[2-amino-5-cyano-6-(methyloxy)pyrimidin-4-yl]-N-(3-bromophenyl)-N~2~-methyl-L-alaninamide |  Chiral |
| 182 | phenylmethyl N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alpha-glutaminate |  Chiral |
| 183 | N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-O-(phenylmethyl)-N-[3-(trifluoromethyl)phenyl]-L-serinamide |  Chiral |
| 184 | N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N~5~,N~5~-bis[2-(methyloxy)ethyl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide |  Chiral |
| 185 | 1,1-dimethylethyl ((4S)-4-{[2-amino-5-cyano-6-(methyloxy)pyrimidin-4-yl]amino}-5-oxo-5-{[3-(trifluoromethyl)phenyl]amino}pentyl)carbamate |  Chiral |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 186 | N~5~-acetyl-N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide |  Chiral |
| 187 | N~5~-acetyl-N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide |  Chiral |
| 188 | N~2~-[2-amino-5-cyano-6-(methyloxy)pyrimidin-4-yl]-N~2~-methyl-N-{3-[(trifluoromethyl)oxy]phenyl}-L-alaninamide |  |
| 189 | methyl 3-({N-[2-amino-5-cyano-6-(methyloxy)pyrimidin-4-yl]-L-alanyl}amino)-5-(trifluoromethyl)benzoate |  |
| 190 | 3-({N-[2-amino-5-cyano-6-(methyloxy)pyrimidin-4-yl]-L-alanyl}amino)-N-[2-(dimethylamino)ethyl]-5-(trifluoromethyl)benzamide |  Chiral |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 191 | N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-3-morpholin-4-yl-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  Chiral |
| 192 | N~2~-[2-amino-5-cyano-6-(methyloxy)pyrimidin-4-yl]-3-morpholin-4-yl-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  Chiral |
| 193 | N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-3-morpholin-4-yl-N-[3-(trifluoromethyl)phenyl]-L-alaninamide |  Chiral |
| 194 | N~5~-(aminocarbonyl)-N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide |  Chiral |
| 195 | N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-D-lysinamide |  Chiral |

**Table 1**

| Entry | Name | Structure |
|---|---|---|
| 196 | N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-D-lysinamide |  |
| 197 | N~2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-O-methyl-N-[3-(trifluoromethyl)phenyl]-L-serinamide |  |
| 198 | N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N~5~-(methylsulfonyl)-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide |  |

**[0056]** Embodiment [0056]: Another aspect of the invention is a pharmaceutical composition comprising the compound according to any one of Embodiments ~~paragraphs~~ [0022]-[0055] and a pharmaceutically acceptable carrier.

**[0057]** Embodiment [0057]: Another aspect of the invention is a metabolite of the compound or the pharmaceutical composition according to any one of Embodiments ~~paragraphs~~ [0022]-[0056].

**[0058]** Embodiment [0058]: Another aspect of the invention is a method of modulating the *in vivo* activity of a kinase, the method comprising administering to a subject an effective amount of a composition comprising at least one of: the compound according to any of Embodiments ~~paragraphs~~ [0022]-[0055], the pharmaceutical composition according to Embodiment ~~paragraph~~

[0056], a compound explicitly provided against in Embodiment ~~paragraph~~ [0022] or [0042], and a pharmaceutical composition comprising a compound, the composition of which was, explicitly provided against in Embodiment ~~paragraph~~ [0022] or [0042] and a pharmaceutically acceptable carrier.

**[0059]** Embodiment [0059]: Another aspect of the invention is the method according to Embodiment ~~paragraph~~ [0058], wherein the kinase is p70S6K.

**[0060]** Embodiment [0060]: Another aspect of the invention is the method according to Embodiment ~~paragraph~~ [0059], wherein modulating the *in vivo* activity of p70S6K comprises inhibition of p70S6K.

**[0061]** Embodiment [0061]: Another aspect of the invention is a method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of a composition comprising at least one of: the compound according to any of Embodiments ~~paragraphs~~ [0022]-[0055], the pharmaceutical composition according to Embodiment ~~paragraph~~ [0056], a compound, the composition of which was, explicitly provided against in Embodiment ~~paragraph~~ [0022] or [0042], and a pharmaceutical composition comprising a compound, the composition of which was, explicitly provided against in Embodiment ~~paragraph~~ [0022] or [0042] and a pharmaceutically acceptable carrier.

**[0062]** Embodiment [0062]: Another aspect of the invention is a method of screening for modulator of a p70S6K kinase, the method comprising combining either a compound according to any one of Embodiments ~~paragraphs~~ [0022]-[0055] or a compound, the composition of which was, explicitly provided against in Embodiment ~~paragraph~~ [0022] or [0042], and at least one candidate agent and determining the effect of the candidate agent on the activity of said kinase.

**[0063]** Embodiment [0063]: Another aspect of the invention is a method of inhibiting proliferative activity in a cell, the method comprising administering an effective amount of: the compound according to any of Embodiments ~~paragraphs~~ [0022]-[0055], the pharmaceutical composition according to Embodiment ~~paragraph~~ [0056], a compound, the composition of which was, explicitly provided against in Embodiment ~~paragraph~~ [0022] or [0042], and a pharmaceutical composition comprising a compound, the composition of which was, explicitly

provided against in Embodiment ~~paragraph~~ [0022] or [0042] and a pharmaceutically acceptable carrier.

**[0064]** Embodiment [0064]: Another aspect of the invention is a method of inhibiting abnormal metabolic activity in a cell, the method comprising administering an effective amount of: the compound according to any of Embodiments ~~paragraphs~~ [0022]-[0055], the pharmaceutical composition according to Embodiment ~~paragraph~~ [0056], a compound, the composition of which was, explicitly provided against in Embodiment ~~paragraph~~ [0022] or [0042], and a pharmaceutical composition comprising a compound, the composition of which was, explicitly provided against in Embodiment ~~paragraph~~ [0022] or [0042] and a pharmaceutically acceptable carrier.